17:30 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Molecular Partners reports Phase II data for MP0250 in MM

Molecular Partners AG (SIX:MOLN) reported data from seven evaluable patients with relapsed and refractory multiple myeloma (MM) in a Phase II trial showing that 8 mg/kg IV MP0250 every three weeks in combination with Velcade...
20:18 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Aveo reports Phase I data for ficlatuzumab in SCCHN

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 12 evaluable patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who were refractory to cetuximab in a Phase I trial showing that...
20:17 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Aveo reports Phase I data for ficlatuzumab in AML

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 8 evaluable patients with relapsed or refractory acute myelogenous leukemia (AML) in a Phase I trial showing that IV ficlatuzumab (AV-299) plus high-dose IV cytarabine led to 4...
19:16 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Molecular Partners starts Phase II of MP0250 in MM

Molecular Partners AG (SIX:MOLN) began an open-label, European Phase II trial to evaluate MP0250 in combination with Velcade bortezomib plus dexamethasone in about 40 patients with refractory and relapsed multiple myeloma (MM). Patients will receive...
20:16 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

BB3: Ph II GUARD started

Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart surgery and require the use of cardiopulmonary...
01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
00:53 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of the HGF/SF / c-MET / Src and SHH / IGF-1 / IGF1R pathways could help treat pancreatic ductal adenocarcinoma (PDAC). In human PDAC...
19:55 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

MP0250: Additional Ph I data

Additional data from an open-label, dose-escalation, European Phase I trial in 24 patients with advanced or metastatic solid tumors showed that 0.5-12 mg/kg IV MP0250 every 2 weeks led to significant tumor volume reductions in...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

MP0250: Preliminary Phase I data

Preliminary data from 15 patients with advanced or metastatic solid tumors in an open-label, dose-escalation, European Phase I trial showed that 0.5, 1.5, 4 and 8 mg/kg IV MP0250 every 2 weeks led to 2...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Induced pluripotent stem (iPS) cell-derived cholangiocytes for screening bile duct disease therapies

Disease models activin A fibroblast growth factor 10 (FGF10) hepatocyte growth factor/scatter factor (HGF/SF) TGFB1 cystic fibrosis transmembrane conductance regulator (CFTR) University of Cambridge University Health Network...